Technical Analysis for CLLS - Cellectis S.A.

Grade Last Price % Change Price Change
F 16.335 5.18% 0.81
CLLS closed down 8.32 percent on Thursday, May 6, 2021, on 1.49 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical CLLS trend table...

Date Alert Name Type % Chg
Expansion Breakdown Bearish Swing Setup 5.18%
Lower Bollinger Band Walk Weakness 5.18%
Below Lower BB Weakness 5.18%
Down 3 Days in a Row Weakness 5.18%
Down 4 Days in a Row Weakness 5.18%
Down 5 Days in a Row Weakness 5.18%
Lower Bollinger Band Touch Weakness 5.18%
Oversold Stochastic Weakness 5.18%
Spinning Top Other -3.57%
Lower Bollinger Band Walk Weakness -3.57%
Older End-of-Day Signals for CLLS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 2 hours ago
Rose Above Previous Day's High about 6 hours ago
Rose Above Lower Bollinger Band about 6 hours ago
Up 5% about 6 hours ago
Up 3% about 6 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Cellectis S.A. Description

Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company's products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Solid Tumors Acute Myeloid Leukemia Blastoma Leukemia Multiple Myeloma Glioblastoma Hematologic Malignancies Genome Chimeric Antigen Receptor Chronic Lymphocytic Leukemia Lymphocytic Leukemia Acute Lymphoblastic Leukemia Solid Tumor Adoptive Cell Transfer CD19 Cell Product Oncogenes Tumors Of The Hematopoietic And Lymphoid Tissues Cellectis

Is CLLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 34.71
52 Week Low 13.17
Average Volume 345,049
200-Day Moving Average 21.55
50-Day Moving Average 19.68
20-Day Moving Average 18.72
10-Day Moving Average 18.32
Average True Range 1.17
ADX 18.12
+DI 14.22
-DI 35.98
Chandelier Exit (Long, 3 ATRs ) 16.91
Chandelier Exit (Short, 3 ATRs ) 18.88
Upper Bollinger Band 20.92
Lower Bollinger Band 16.51
Percent B (%b) -0.22
BandWidth 23.57
MACD Line -0.88
MACD Signal Line -0.62
MACD Histogram -0.2613
Fundamentals Value
Market Cap 659.81 Million
Num Shares 42.5 Million
EPS -2.24
Price-to-Earnings (P/E) Ratio -6.93
Price-to-Sales 15.95
Price-to-Book 3.54
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.57
Resistance 3 (R3) 17.74 17.24 17.23
Resistance 2 (R2) 17.24 16.72 17.15 17.12
Resistance 1 (R1) 16.38 16.40 16.13 16.21 17.00
Pivot Point 15.88 15.88 15.75 15.79 15.88
Support 1 (S1) 15.02 15.36 14.77 14.85 14.06
Support 2 (S2) 14.52 15.04 14.43 13.94
Support 3 (S3) 13.66 14.52 13.83
Support 4 (S4) 13.49